Ultime notizie per Novo Nordisk (NYSE:NVO) Azioni

NOVO-NORDISK A/S-SPONS ADR

Novo Nordisk

With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.

Siegen,,North,Rhine,Westphalia,,,Germany,-,10,11,2023:

News

Hims & Hers Health, Inc. Class A Common Stock

HIMS

Titolo in forte calo con nuove previsioni al ribasso: analisi tecnica e scenari possibili in un mercato farmaceutico in evoluzione.

Crollo storico per Novo Nordisk: quale futuro dopo la revisione delle guidance?

Novo,Nordisk,Advertising,Logo,On,Facade,Building,,Danish,Pharmaceutical,Healthcare

Biotech

Earnings

Large Cap

Guidance

Health Care

Movers

General

Le quotazioni del gigante farmaceutico in calo. Cosa sta succedendo ai trattamenti per dimagrire? Un&#39;analisi dei motivi dietro il tonfo.

Crollo delle azioni Novo Nordisk: i farmaci per dimagrire non funzionano più?

Wegovy

I giganti farmaceutici celebrano ricavi record. Ma un&#39;insidia nel comportamento dei pazienti minaccia la crescita a lungo termine.

Farmaci anti-obesità: vendite da record, ma c&#39;è un problema

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul class="wp-block-list">
<li>Seaport Global analyst Tom Curran downgraded the rating for Baker Hughes Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BKR#NASDAQ">BKR</a>) from Buy to Neutral. Baker Hughes shares closed at $45.75 on Tuesday. <a href="https://www.benzinga.com/quote/BKR/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Keybanc analyst Aleksey Yefremov downgraded the rating for Albemarle Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALB#NYSE">ALB</a>) from Overweight to Sector Weight. Albemarle shares closed at $71.60 on Tuesday. <a href="https://www.benzinga.com/quote/ALB/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>JP Morgan analyst Brian Ossenbeck downgraded Norfolk Southern Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NSC#NYSE">NSC</a>) from Overweight to Neutral and raised the price target from $282 to $288. Norfolk Southern shares closed at $277.70 on Tuesday. <a href="https://www.benzinga.com/quote/NSC/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Barclays analyst Emily Field downgraded Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) from Overweight to Equal-Weight. Novo Nordisk shares closed at $53.94 on Tuesday. <a href="https://www.benzinga.com/quote/NVO/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Citigroup analyst Ariel Rosa downgraded the rating for Union Pacific Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNP#NYSE">UNP</a>) from Buy to Neutral and slashed the price target from $270 to $250. Union Pacific shares closed at $223.77 on Tuesday. <a href="https://www.benzinga.com/quote/UNP/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying UNP stock? Here&#8217;s what analysts think:
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="599" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/30135615/image-479-1024x599.png" alt="" class="wp-image-1007620" style="width:624px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/30135615/image-479-1024x599.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/30135615/image-479-300x175.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/30135615/image-479-768x449.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/30135615/image-479.png 1117w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/07/46684052/jim-cramer-prefers-this-financial-stock-over-brighthouse-financial">Jim Cramer Prefers This Financial Stock Over Brighthouse Financial</a></li>
</ul>
Photo via Shutterstock

Downgrades

Markets

Analyst Ratings

Trading Ideas

This Union Pacific Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders will search for circumstances when the market estimation of an option diverges heavily from its normal worth. High amounts of trading activity could push option prices to exaggerated or underestimated levels. 
Below are some instances of options activity happening in the Health Care sector: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>REPL</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/21/25</td>
<td>$10.00</td>
<td>$35.0K</td>
<td>3.3K</td>
<td>8.7K</td>
</tr>
<tr>
<td>ALHC</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>08/15/25</td>
<td>$12.50</td>
<td>$250.0K</td>
<td>15.3K</td>
<td>3.8K</td>
</tr>
<tr>
<td>ABBV</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>08/01/25</td>
<td>$182.50</td>
<td>$69.5K</td>
<td>3.3K</td>
<td>918</td>
</tr>
<tr>
<td>PFE</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$22.50</td>
<td>$131.5K</td>
<td>15.7K</td>
<td>518</td>
</tr>
<tr>
<td>HIMS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>08/08/25</td>
<td>$73.00</td>
<td>$79.8K</td>
<td>94</td>
<td>392</td>
</tr>
<tr>
<td>JNJ</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>10/17/25</td>
<td>$175.00</td>
<td>$44.4K</td>
<td>14.4K</td>
<td>321</td>
</tr>
<tr>
<td>NVO</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/20/26</td>
<td>$85.00</td>
<td>$48.7K</td>
<td>180</td>
<td>310</td>
</tr>
<tr>
<td>ACAD</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>08/15/25</td>
<td>$23.00</td>
<td>$40.2K</td>
<td>810</td>
<td>257</td>
</tr>
<tr>
<td>HUM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$220.00</td>
<td>$170.0K</td>
<td>183</td>
<td>220</td>
</tr>
<tr>
<td>BBIO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>08/15/25</td>
<td>$45.00</td>
<td>$48.0K</td>
<td>1.5K</td>
<td>208</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These itemized elaborations have been created using the accompanying table. 
• For REPL (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REPL#NASDAQ">REPL</a>), we notice a call option sweep that happens to be bearish, expiring in 114 day(s) on November 21, 2025. This event was a transfer of 250 contract(s) at a $10.00 strike. This particular call needed to be split into 5 different trades to become filled. The total cost received by the writing party (or parties) was $35.0K, with a price of $140.0 per contract. There were 3310 open contracts at this strike prior to today, and today 8715 contract(s) were bought and sold. 
• For ALHC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALHC#NASDAQ">ALHC</a>), we notice a call option trade that happens to be bullish, expiring in 16 day(s) on August 15, 2025. This event was a transfer of 2000 contract(s) at a $12.50 strike. The total cost received by the writing party (or parties) was $250.0K, with a price of $125.0 per contract. There were 15302 open contracts at this strike prior to today, and today 3811 contract(s) were bought and sold. 
• Regarding ABBV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>), we observe a put option sweep with bearish sentiment. It expires in 2 day(s) on August 1, 2025. Parties traded 499 contract(s) at a $182.50 strike. This particular put needed to be split into 33 different trades to become filled. The total cost received by the writing party (or parties) was $69.5K, with a price of $142.0 per contract. There were 3330 open contracts at this strike prior to today, and today 918 contract(s) were bought and sold. 
• Regarding PFE (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>), we observe a call option sweep with bearish sentiment. It expires in 170 day(s) on January 16, 2026. Parties traded 500 contract(s) at a $22.50 strike. This particular call needed to be split into 11 different trades to become filled. The total cost received by the writing party (or parties) was $131.5K, with a price of $263.0 per contract. There were 15788 open contracts at this strike prior to today, and today 518 contract(s) were bought and sold. 
• Regarding HIMS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>), we observe a call option sweep with bullish sentiment. It expires in 9 day(s) on August 8, 2025. Parties traded 235 contract(s) at a $73.00 strike. This particular call needed to be split into 24 different trades to become filled. The total cost received by the writing party (or parties) was $79.8K, with a price of $340.0 per contract. There were 94 open contracts at this strike prior to today, and today 392 contract(s) were bought and sold. 
• For JNJ (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>), we notice a call option trade that happens to be bullish, expiring in 79 day(s) on October 17, 2025. This event was a transfer of 200 contract(s) at a $175.00 strike. The total cost received by the writing party (or parties) was $44.4K, with a price of $222.0 per contract. There were 14487 open contracts at this strike prior to today, and today 321 contract(s) were bought and sold. 
• Regarding NVO (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>), we observe a put option trade with bullish sentiment. It expires in 233 day(s) on March 20, 2026. Parties traded 14 contract(s) at a $85.00 strike. The total cost received by the writing party (or parties) was $48.7K, with a price of $3480.0 per contract. There were 180 open contracts at this strike prior to today, and today 310 contract(s) were bought and sold. 
• For ACAD (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACAD#NASDAQ">ACAD</a>), we notice a call option trade that happens to be bullish, expiring in 16 day(s) on August 15, 2025. This event was a transfer of 244 contract(s) at a $23.00 strike. The total cost received by the writing party (or parties) was $40.2K, with a price of $165.0 per contract. There were 810 open contracts at this strike prior to today, and today 257 contract(s) were bought and sold. 
• For HUM (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>), we notice a call option trade that happens to be bullish, expiring in 534 day(s) on January 15, 2027. This event was a transfer of 25 contract(s) at a $220.00 strike. The total cost received by the writing party (or parties) was $170.0K, with a price of $6800.0 per contract. There were 183 open contracts at this strike prior to today, and today 220 contract(s) were bought and sold. 
• Regarding BBIO (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BBIO#NASDAQ">BBIO</a>), we observe a call option sweep with bearish sentiment. It expires in 16 day(s) on August 15, 2025. Parties traded 160 contract(s) at a $45.00 strike. This particular call needed to be split into 12 different trades to become filled. The total cost received by the writing party (or parties) was $48.0K, with a price of $300.0 per contract. There were 1591 open contracts at this strike prior to today, and today 208 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more news on unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Options

ABBV

ACAD

ALHC

BBIO

REPL

10 Health Care Stocks Whale Activity In Today's Session

Shares of Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) are trading lower Wednesday morning, extending a dramatic sell-off from Tuesday&#8217;s session. Here&#8217;s what investors <a href="https://www.benzinga.com/quote/NVO/news">need to know</a>.
What To Know: The downward momentum follows Tuesday&#8217;s announcement where the Danish pharmaceutical giant slashed its 2025 financial outlook for the second time this year, sending its stock plummeting by as much as 25%.
The <a href="https://www.benzinga.com/news/health-care/25/07/46685132/ozempic-and-wegovy-maker-cuts-outlook-in-surprise-move-picks-new-ceo">revised forecast</a>, which cut projected 2025 sales growth from a range of 13-21% down to 8-14%, was primarily blamed on persistent headwinds. 
The company cited the unabated use of compounded GLP-1 alternatives in the United States, which has <a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/07/46688728/novo-nordisk-weight-loss-stock-eli-lilly-wegovy-ozempic">undercut demand</a> for its blockbuster weight-loss drug Wegovy and diabetes treatment Ozempic. 
Slower-than-expected market expansion and heightened competition, particularly from Eli Lilly And Co&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) Zepbound, also contributed to the downgrade.
Adding to the negative sentiment, Barclays analyst Emily Field <a href="https://www.benzinga.com/quote/NVO/analyst-ratings">downgraded</a> NVO from Overweight to Equal-Weight on Wednesday, fueling concerns about the company&#8217;s near-term growth prospects. The turmoil coincides with a leadership shakeup, with Maziar Mike Doustdar set to take over as CEO on August 7. 
He faces the immediate challenge of restoring investor confidence by navigating the intense competitive landscape and tackling the unresolved issue of unregulated compounded drugs impacting the company&#8217;s key revenue streams.
Benzinga Edge Rankings: According to <a href="http://benzinga.grsm.io/register174">Benzinga Edge</a> stock rankings, Novo Nordisk presents a mixed but telling financial profile. The stock scores strongly on Quality with a rating of 73.01, indicating it is a financially healthy and profitable company. Its Growth score is moderate at 53.84. 
However, the data highlights significant concerns for investors. The Momentum score is extremely low at 12.38, reflecting the recent sharp sell-off, a fact corroborated by negative price trend indicators across short, medium, and long-term horizons. 
Furthermore, its Value score is a very low 7.73, suggesting the stock is considered expensive relative to its fundamentals, even after the recent price drop.
Price Action: According to data from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, NVO shares are trading lower by 6.18% to $50.61 Wednesday morning. The stock has a 52-week high of $139.74 and a 52-week low of $50.57.
Read Also: <a href="https://www.benzinga.com/m-a/25/07/46701164/bausch-health-adds-late-stage-ready-alcohol-liver-disease-drug-candidate-in-63-million-durect-buyout">Bausch Health Adds Late-Stage Ready Alcohol Liver Disease Drug Candidate In $63 Million DURECT Buyout</a>
<h2 class="wp-block-heading">How To Buy NVO Stock</h2>
By now you're likely curious about how to participate in the market for Novo Nordisk &#8211; be it to purchase shares, or even attempt to bet against the company.
Buying shares is typically done through a brokerage account. You can find a list of <a href="https://www.benzinga.com/money/best-stock-trading-platforms">possible trading platforms here.</a> Many will allow you to buy &#8220;fractional shares,&#8221; which allows you to own portions of stock without buying an entire share.
In the case of Novo Nordisk, which is trading at $50.61 as of publishing time, $100 would buy you 1.976 shares of stock.
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to &#8220;go short&#8221; a share of stock by lending you the shares to sell. The process of shorting a <a href="https://www.benzinga.com/money/how-to-short-a-stock">stock can be found at this resource.</a> Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading &#8211; either way it allows you to profit off of the share price decline.
Image: Shutterstock

Novo Nordisk Stock Hits New 52-Week Low Amid Profit Warning: What Investors Need To Know

<ul>
<li>UNH</li>
<li>SOFI</li>
<li>GLD</li>
<li>AMD</li>
<li>NVDA</li>
<li>META</li>
<li>HOOD</li>
<li>AAPL</li>
<li>TSLA</li>
<li>NVO</li>
</ul>
Data from <a href="https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment">https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment</a>
&nbsp;

AAPL

HOOD

NVDA

SOFI

TSLA

Top 10 Trending Stocks On WallStreetBets As Of July 30, 2025 (Via Swaggy Stocks)

Barclays analyst Emily Field downgrades Novo Nordisk (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) from Overweight to Equal-Weight.

Barclays Downgrades Novo Nordisk to Equal-Weight

Weight-loss drugmaker Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>)&#8217;s technical chart is displaying a largely bearish trend amid a profit warning issued by the company tied to its blockbuster obesity drug Wegovy. However, this expert believes that the Danish pharmaceutical giant could have avoided some trouble if it hadn&#8217;t ended its partnership with Hims &amp; Hers Health Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>).
Check out <a href="https://www.benzinga.com/quote/NVO">NVO stock price here</a>.
What Happened: Novo&#8217;s stock <a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/07/46688728/novo-nordisk-weight-loss-stock-eli-lilly-wegovy-ozempic">plunged by 21.83%</a> on Tuesday after the pharma company said that it expects 2025 sales to grow 8%–14%, down from a previous range of 13%–21%. 
The firm also cut its operating profit forecast to 10%–16%, from 16%–24%, marking the second guidance cut of the year.
Shay Bolor, the chief market strategist at Futurum Equities, argues that if Novo Nordisk had partnered more effectively with HIMS, rather than ending it, it could have leveraged HIMS' direct-to-customer consumer layer to maintain market dominance.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><a href="https://twitter.com/search?q=%24NVO&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$NVO</a> IS AN ABSOLUTE MESS Today's $60B drawdown is one of the most ironic moments I've seen. This could've played out VERY differently if they had embraced <a href="https://twitter.com/search?q=%24HIMS&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$HIMS</a> instead of dismissing the disruptor building the consumer layer they clearly weren't ready to own. Novo just lost 5x… <a href="https://t.co/uJjO8rtMVr">pic.twitter.com/uJjO8rtMVr</a>
&mdash; Shay Boloor (@StockSavvyShay) <a href="https://twitter.com/StockSavvyShay/status/1950159658511192156?ref_src=twsrc%5Etfw">July 29, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Bolor&#8217;s post comes as Hims &amp; Hers <a href="https://www.businesswire.com/news/home/20250729936547/en/Hims-Hers-Data-Shows-Personalized-GLP-1-Plans-Drive-Real-Weight-Loss-Few-Side-Effects-and-Strong-Adherence-to-Care">reported</a> an average weight loss of 10.3% among customers using their personalized GLP-1 weight loss plans, with a 75% patient retention rate over six months. 
Novo&#8217;s technical chart shows that its stock price of $53.94 after a 21.83% decline on Tuesday was below its short and long-term daily simple moving averages.
According to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>, its MACD line was below zero at -1.58, and it trended lower than the signal line at -0.6, which signals a worsening bearish trend as its 26-day exponential moving average was below its 12-day EMA.
However, its relative strength index at 26.39 was in the oversold zone, indicating that it could bounce back from those levels.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="576" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/30052909/NOVO-Tech-Chart-1024x576.png" alt="" class="wp-image-1006700" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/30052909/NOVO-Tech-Chart-1024x576.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/30052909/NOVO-Tech-Chart-300x169.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/30052909/NOVO-Tech-Chart-768x432.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/30052909/NOVO-Tech-Chart-1536x864.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/30052909/NOVO-Tech-Chart.png 1920w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
See Also:&nbsp;<a href="https://www.benzinga.com/crypto/cryptocurrency/25/07/46513468/bitcoin-miner-iren-could-surge-1572-as-sotp-valuation-pegs-300-target-hedge-fund-manager-eric-jackson-says-were-cooking-with-gas" target="_blank" rel="noreferrer noopener">Bitcoin Miner IREN Could Surge 1,572% As SOTP Valuation Pegs $300 Target — Hedge Fund Manager Eric Jackson Says, ‘We&#8217;re Cooking With Gas&#8217;</a>
Why It Matters: Novo Nordisk <a href="https://www.benzinga.com/markets/equities/25/06/46067629/hims-ceo-slams-novo-nordisk-for-anticompetitive-demands-after-ozempic-maker-abruptly-ends-partnership-we-refuse-to-be-strong-armed">ended its collaboration</a> with Hims &amp; Hers in June, citing the telehealth company&#8217;s alleged violation of laws prohibiting mass sales of compounded drugs under the guise of "personalization" and deceptive marketing practices that compromise patient safety.
According to Reuters, both firms are now battling it out in the courts as they have filed several lawsuits against each other.
Price Action: After the 21.83% drop, Novo shares rose 0.83% in after-hours. On Friday, it was down 3.60% in premarket. The stock was down 38.37% year-to-date and 58.26% over the past year.
Benzinga's Edge Stock Rankings indicate that NVO maintains a poor momentum across short, medium, and long-term periods. Also, the stock scores poorly on value rankings, but its quality rating remains relatively strong. Additional performance details are <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-3/#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">available here</a>.
<figure class="wp-block-image size-large"><a href="https://www.benzinga.com/premium/ideas/benzinga-edge-3/#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound"><img loading="lazy" decoding="async" width="1024" height="155" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/30052749/NVO-EDGE-1024x155.png" alt="" class="wp-image-1006695" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/30052749/NVO-EDGE-1024x155.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/30052749/NVO-EDGE-300x45.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/30052749/NVO-EDGE-768x116.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/30052749/NVO-EDGE.png 1273w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
The&nbsp;SPDR S&amp;P 500 ETF Trust&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and&nbsp;Invesco QQQ Trust ETF&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which track the S&amp;P 500 index and Nasdaq 100 index, respectively, were higher in premarket on Wednesday. The SPY was up 0.12% at $636.02, while the QQQ advanced 0.23% to $568.57, according to&nbsp;<a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>&nbsp;data.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/hedge-funds/25/07/46687204/warren-buffett-has-56-of-his-258-billion-portfolios-value-exposed-to-ai-here-are-the-5-stocks-that-are-leveraging-ai-within-berkshires-holdings" target="_blank" rel="noreferrer noopener">Warren Buffett Has 56% Of His $258 Billion Portfolio&#8217;s Value Exposed To AI: Here Are The 5 Stocks That Are Leveraging AI Within Berkshire&#8217;s Holdings</a> </li>
</ul>
Photo by Tobias Arhelger via Shutterstock

Novo Nordisk Charts Signal Weakness Amid Wegovy Warning, Expert Says 'Could've Played Out VERY Differently If They Had Embraced $HIMS'

WIIM

Novo Nordisk shares are trading lower after the company on Tuesday lowered its 2025 sales outlook, citing reduced growth expectations for Wegovy and Ozempic in the US and weaker Wegovy penetration.

U.S. markets closed lower on Tuesday, with the Dow Jones Industrial Average slipping nearly 0.5% to 44,632.99 and the S&amp;P 500 declining 0.3% to 6,370.86. The Nasdaq dropped close to 0.4%, finishing at 21,098.29.
These are the top stocks that gained the attention of retail traders and investors throughout the day:
UnitedHealth Group&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>)
UnitedHealth Group saw a decline of 7.46%, closing at $261.07. The stock fluctuated between an intraday high of $272.91 and a low of $260.55, with its 52-week range spanning from $248.88 to $630.73. In the after-hours session, the shares rose by almost 0.7%.
The company&#8217;s <a href="https://www.benzinga.com/markets/earnings/25/07/46688163/unitedhealth-misses-q2-mark-but-vows-a-healthier-2026">second-quarter earnings</a> report revealed adjusted earnings of $4.08, falling short of the expected $4.95. Despite this, UnitedHealth reaffirmed its 2025 guidance, aiming for a healthier outlook in the coming years.
Starbucks Corp&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBUX#NASDAQ">SBUX</a>)
Starbucks shares dipped 0.76%, ending the day at $92.96. The stock&#8217;s intraday movement saw a high of $94.39 and a low of $91.78, while its 52-week high and low are $117.46 and $72.72. The shares spiked 4.6% to $97.25 in the after-hours trading.
The coffee giant reported third-quarter results, with <a href="https://www.benzinga.com/markets/earnings/25/07/46706017/starbucks-q3-earnings-revenue-beat-eps-miss-turnaround-efforts-ahead-of-schedule">revenue surpassing expectations</a> but earnings per share of 50 cents per share missing the analyst estimates of 65 cents per share. However, Starbucks&#8217; turnaround efforts are reportedly ahead of schedule.
Novo Nordisk A/S&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>)
Novo Nordisk&#8217;s stock plummeted 21.83%, closing at $53.94. The day&#8217;s trading saw a high of $55.37 and a low of $53.51, with a 52-week range from $53.51 to $139.74. The pharmaceutical company <a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/07/46688728/novo-nordisk-weight-loss-stock-eli-lilly-wegovy-ozempic">issued a profit warning</a> related to its obesity drug Wegovy, leading to a significant drop in its share price. The company also adjusted its sales and profit forecasts for 2025.
United Parcel Service Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UPS#NYSE">UPS</a>)
UPS shares fell 10.57%, closing at $90.84. The stock&#8217;s intraday high was $98.18, with a low of $90.72, and its 52-week range is $90.55 to $145.01. The logistics giant&#8217;s second-quarter results exceeded revenue expectations but <a href="https://www.benzinga.com/markets/earnings/25/07/46687002/ups-volume-takes-a-hit-on-tariff-induced-weakness-withholds-annual-outlook">narrowly missed earnings estimates</a>. The company continues to face challenges in the global trade environment.
Meta Platforms&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>)
Meta Platforms saw a 2.46% decline, closing at $700. The stock reached an intraday high of $724.47 and a low of $699.91, with its 52-week range from $450.80 to $747.90. As one of the top-performing stocks in 2025, Meta is <a href="https://www.benzinga.com/trading-ideas/previews/25/07/46703548/meta-q2-preview-11-straight-revenue-beats-on-line-with-stock-near-all-time-highs">set to report</a> its second-quarter financial results on Wednesday, with expectations of highlighting its AI investments.
Benzinga's Edge Stock Rankings indicate Meta Platforms checks out on Short, Medium and Long Price Trend. Here is <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">how the stock is ranked</a> on other metrics.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound"><img loading="lazy" decoding="async" width="445" height="283" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/29215905/Screenshot-2025-07-30-at-10.58.54.png" alt="" class="wp-image-1006079" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/29215905/Screenshot-2025-07-30-at-10.58.54.png 445w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/29215905/Screenshot-2025-07-30-at-10.58.54-300x191.png 300w" sizes="(max-width: 445px) 100vw, 445px" /></a></figure>
Prepare for the day&#8217;s trading&nbsp;<a href="https://editorial.benzinga.com/wp-admin/Premarket%20Movers%20&amp;%20News">with top premarket movers and news</a>&nbsp;by Benzinga.
Photo Courtesy: Supawat Bursuk on Shutterstock.com
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/etfs/broad-u-s-equity-etfs/25/07/46710463/cathie-woods-15m-crypto-bet-sells-bitcoin-king-block-doubles-down-on-ethereum-giant-bitmine-immersion">Cathie Wood&#8217;s $15M Crypto Bet: Sells Bitcoin King Block, Doubles Down On Ethereum Giant Bitmine Immersion</a></li>
</ul>
This story was generated using <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and edited by <a href="https://www.benzinga.com/author/shivdeep-dhaliwal" target="_blank" rel="noreferrer noopener">Shivdeep Dhaliwal</a>

Equities

SBUX

Unitedhealth, Starbucks, Novo Nordisk, UPS And Meta: Why These 5 Stocks Are On Investors' Radars Today

Risk appetite took a breather Tuesday, with major U.S. stock indices retreating modestly from record highs as investors braced for a pivotal stretch of <a href="https://www.benzinga.com/markets/earnings/25/07/46693997/wall-street-earnings-preview-microsoft-apple-meta-amazon-mastercard-visa">earnings and macro events.</a>
<ul class="wp-block-list">
<li>MAGS ETF is up 50% since April&#8217;s tariff-driven low. <a href="https://www.benzinga.com/quote/MAGS">Track it now here.</a></li>
</ul>
Roughly $19.5 trillion in market value — led by four Magnificent Seven names: Microsoft Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>), Meta Platforms Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>), Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>), and Amazon.com Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) — is set to report earnings by Thursday after market close.
Meanwhile, the Federal Reserve is widely expected to keep rates steady at 4.25%-4.5% on Wednesday, though growing market chatter points to possible dissent in favor of early cuts.
A 90-day extension of the U.S.-China trade truce remains on the table, said U.S. Secretary of Commerce Howard Lutnick.
Attention will then shift to Thursday's heavy macro lineup, including second-quarter GDP growth estimates and June's PCE inflation data, followed by July's jobs report on Friday — key inputs for the Fed's next move.
By midday in New York, the S&amp;P 500 slipped 0.1%, the Dow Jones Industrial Average declined 0.4%, and the Russell 2000 shed 0.7%. The Nasdaq 100 remained flat.
Advanced Micro Devices Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) surged past $175, breaching a major technical level and marking highs not seen since July 2014, making it one of the day's top tech performers. 
Shares of AMD have now rallied by 134% since April&#8217;s tariff-driven lows, outperforming NVIDIA Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>)&#8217;s 105% gain during the same period.
The U.S. dollar extended its rally, on pace for a fourth consecutive gain after Monday's sharp move.
In commodities, oil prices stayed hot. WTI crude rose 1.6% to $67.75 per barrel, extending Monday's 2.4% jump and hitting a two-week high. Precious metals traded sideways as dollar strength continued to limit upside momentum.
Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) edged down 1% to $117,000, logging a second straight daily decline.
<h2 class="wp-block-heading">Tuesday&#8217;s Performance In Major U.S. Indices, ETFs</h2>
<figure class="wp-block-table is-style-stripes"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Major Indices </td>
<td>Price</td>
<td>1-day % chg</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>23,364.69</td>
<td>0.0%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>6,380.21</td>
<td>-0.1%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>44,657.34</td>
<td>-0.4%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>2,241.90</td>
<td>-0.7%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated by 12:20 p.m. ET</figcaption></figure>
According to&nbsp;<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent&amp;t=be2bearmibe3na1">Benzinga Pro</a>&nbsp;data:
<ul class="wp-block-list">
<li>The&nbsp;Vanguard S&amp;P 500 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VOO#NYSE">VOO</a>) was down 0.092% to $584.90.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>) slipped 0.4% to $446.42.</li>
<li>The tech-heavy&nbsp;Invesco QQQ Trust Series&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>)&nbsp;flattened at $567.97.</li>
<li>The&nbsp;iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) fell 0.8% to $222.45.</li>
<li>The&nbsp;Industrials&nbsp;Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLI#NYSE">XLI</a>) underperformed, down 1.3%; the&nbsp;Real Estate&nbsp;Select Sector SPDR Fund&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLRE#NYSE">XLRE</a>) outperformed, up 1.3%.</li>
</ul>
<h2 class="wp-block-heading">Tuesday&#8217;s Stock Movers</h2>
<ul class="wp-block-list">
<li>Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) plunged 22.5% after the Danish pharma giant slashed guidance on its blockbuster Wegovy weight-loss drug, while also <a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/07/46688728/novo-nordisk-weight-loss-stock-eli-lilly-wegovy-ozempic">announcing a new CEO.</a></li>
<li>Sarepta Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) surged more than 20% after announcing that the U.S. Food and Drug Administration signaled it could resume shipments of Elevidys.</li>
</ul>
Stocks reacting to quarterly results included:
<ul class="wp-block-list">
<li>Procter &amp; Gamble Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PG#NYSE">PG</a>) flat at 0.0%</li>
<li>UnitedHealth Group Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) down 5.1%</li>
<li>Merck &amp; Co., Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) down 3.3%</li>
<li>Boeing Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>) down 3.0%</li>
<li>Spotify Technology S.A. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPOT#NYSE">SPOT</a>) down 11.8%</li>
<li>American Tower Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMT#NYSE">AMT</a>) down 3.0%</li>
<li>Royal Caribbean Cruises Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RCL#NYSE">RCL</a>) down 5.0%</li>
<li>United Parcel Service, Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UPS#NYSE">UPS</a>) down 9.7%</li>
<li>Ecolab Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ECL#NYSE">ECL</a>) down 4.7%</li>
<li>PayPal Holdings, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PYPL#NASDAQ">PYPL</a>) down 9.3%</li>
<li>Johnson Controls International plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JCI#NYSE">JCI</a>) down 6.9%</li>
<li>Norfolk Southern Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NSC#NYSE">NSC</a>) down 3.5%</li>
<li>Carrier Global Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CARR#NYSE">CARR</a>) down 11.0%</li>
<li>Corning Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GLW#NYSE">GLW</a>) up 13.2%</li>
<li>CBRE Group, Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CBRE#NYSE">CBRE</a>) up 9.1%</li>
<li>Sysco Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYY#NYSE">SYY</a>) down 2.5%</li>
<li>DTE Energy Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DTE#NYSE">DTE</a>) up 0.2%</li>
<li>SoFi Technologies, Inc.(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOFI#NASDAQ">SOFI</a>) up 14.0%</li>
<li>Hubbell Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUBB#NYSE">HUBB</a>) down 2.6%</li>
<li>Incyte Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>) up 8.6%</li>
<li>Stanley Black &amp; Decker, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SWK#NYSE">SWK</a>) down 8.4%</li>
<li>PJT Partners Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PJT#NYSE">PJT</a>) down 2.0%</li>
<li>Polaris Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PII#NYSE">PII</a>) up 12.2%</li>
<li>JetBlue Airways Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JBLU#NASDAQ">JBLU</a>) up 4.9%</li>
</ul>
Stocks scheduled to report earnings after Tuesday's close include BXP Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BXP#NYSE">BXP</a>), Caesars Entertainment Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CZR#NASDAQ">CZR</a>), Electronic Arts Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EA#NASDAQ">EA</a>), Essex Property Trust Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ESS#NYSE">ESS</a>), Exelixis Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NASDAQ">EXEL</a>), Mondelez International Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDLZ#NASDAQ">MDLZ</a>), PPG Industries Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PPG#NYSE">PPG</a>), Regency Centers Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REG#NASDAQ">REG</a>), Republic Services Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RSG#NYSE">RSG</a>), Starbucks Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBUX#NASDAQ">SBUX</a>), Seagate Technology Holdings PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STX#NASDAQ">STX</a>), Teradyne Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TER#NASDAQ">TER</a>), Visa Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/V#NYSE">V</a>), Booking Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BKNG#NASDAQ">BKNG</a>), The Cheesecake Factory Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAKE#NASDAQ">CAKE</a>), Freshworks Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FRSH#NASDAQ">FRSH</a>), Pebblebrook Hotel Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PEB#NYSE">PEB</a>), Qorvo Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QRVO#NASDAQ">QRVO</a>) and Red Rock Resorts Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RRR#NASDAQ">RRR</a>).
Read Now:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/forex/25/07/46673546/us-eu-trade-deal-dollar-surge-trump">Trump&#8217;s Charm Offense In Europe Unleashes Dollar Thunder</a> Photo: Shutterstok<a href="https://www.benzinga.com/markets/forex/25/07/46673546/us-eu-trade-deal-dollar-surge-trump"> </a></li>
</ul>

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Government

Broad U.S. Equity ETFs

Commodities

Economics

Federal Reserve

Tech

ETFs

$BTC

AMZN

BKNG

CAKE

CARR

CBRE

SPDR Dow Jones Industrial Average ETF Trust

EXEL

FRSH

HUBB

INCY

JBLU

MDLZ

MSFT

PYPL

QRVO

SPOT

SRPT

XLRE

AMD Rises To 1-Year Highs, Crude Eyes $68: What's Moving Markets Tuesday?

Eli Lilly and Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) stock is trading lower on Tuesday after its weight loss drug rival, Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>), trimmed its 2025 financial outlook.
The cut marks the&nbsp;<a target="_blank" href="https://www.benzinga.com/25/05/45252150/novo-nordisk-expects-fda-decision-for-oral-wegovy-by-end-of-2025-reports-mixed-q1-earnings" rel="noreferrer noopener">second time this year</a> Novo Nordisk has lowered its guidance.
Novo Nordisk now projects 2025 sales growth to be 8-14% at constant exchange rates, a notable reduction from its earlier forecast of 13-21%.
Similarly, the outlook for operating profit growth has been lowered to 10-16% from the previously anticipated 16-24%.
This revised guidance largely stems from a slower-than-expected penetration of its branded GLP-1 treatments, particularly in the United States, a market increasingly impacted by the persistent use of <a target="_blank" href="https://www.benzinga.com/news/health-care/25/07/46685132/ozempic-and-wegovy-maker-cuts-outlook-in-surprise-move-picks-new-ceo" rel="noreferrer noopener">compounded GLP-1 alternatives</a>.
<h2 class="wp-block-heading">GLP-1 Drugs</h2>
In a letter to the U.S. Food and Drug Administration (FDA) Commissioner&nbsp;Marty Makary on Friday, over 80 bipartisan members asked the&nbsp;agency to stop counterfeit and copycat versions of GLP-1 drugs like&nbsp;Novo Nordisk&#8217;s Wegovy (semaglutide) and&nbsp;Eli Lilly&#8217;s Zepbound&nbsp;<a target="_blank" href="https://www.benzinga.com/topic/weight-loss" rel="noreferrer noopener">from flooding the market</a>.
The group wrote&nbsp;the letter urging immediate action against the rising threat of illegal, counterfeit anti-obesity medications entering the U.S.&nbsp;
The group urged the FDA to issue warning letters, pursue civil enforcement, and monitor non-compliant online retailers and compounding pharmacies selling <a target="_blank" href="https://www.benzinga.com/news/fda/25/07/46641326/congress-sounds-alarm-over-illegal-weight-loss-drug-imports-from-china" rel="noreferrer noopener">unapproved weight-loss drugs</a>.
In April, after media reports on Hims &amp; Hers Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>) partnering with the company, Eli Lilly said in a statement that it has no affiliation with Hims &amp; Hers.
Zepbound (tirzepatide) can be prescribed by any licensed healthcare professional. People who are commercially insured with coverage for&nbsp;Zepbound&nbsp;may be eligible to pay as little as&nbsp;$25.
<h2 class="wp-block-heading">Trial Data</h2>
On Tuesday, Eli Lilly also released topline results from the Phase 3 BRUIN CLL-314 trial of Jaypirca (pirtobrutinib) versus Imbruvica (ibrutinib) in patients with chronic lymphocytic leukemia or <a target="_blank" href="https://www.benzinga.com/pressreleases/25/07/n46682559/lillys-jaypirca-pirtobrutinib-the-first-and-only-approved-non-covalent-reversible-btk-inhibitor-me" rel="noreferrer noopener">small lymphocytic lymphoma (CLL/SLL)</a>.
Johnson &amp; Johnson&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) Imbruvica is a covalent BTK inhibitor.
The study enrolled patients with treatment-naïve CLL/SLL and those previously treated but were BTK inhibitor-naïve.
The study met its primary endpoint of non-inferiority on overall response rate (ORR) as assessed by an independent review committee (IRC) in both the pre-treated and intent-to-treat populations.
ORR favored pirtobrutinib with a nominal P-value for superiority&nbsp;(p &lt;0.05). Progression-free survival (PFS), a key secondary endpoint, was not yet mature at this analysis, but was trending toward pirtobrutinib.
BRUIN CLL-314 is the first ever head-to-head trial versus ibrutinib in CLL to include treatment-naïve patients.
The overall safety profile of pirtobrutinib in BRUIN CLL-314 was similar to previously reported trials. Detailed results will be presented at a medical congress later in 2025.
These data build on the previously reported positive results from the BRUIN Phase 1/2 trial and the Phase 3 BRUIN CLL-321 trial, the first randomized, controlled study ever conducted in an exclusively post-covalent BTK inhibitor population.
The BRUIN CLL-313 Phase 3 study of pirtobrutinib versus chemoimmunotherapy in treatment naïve CLL/SLL is expected to read out later in 2025 and combined with the results of BRUIN CLL-314, will form the basis of regulatory submissions globally.
Price Action: LLY stock is down 4.93% at $768.27 at the last check on Tuesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/earnings/25/07/46687653/sofi-technologies-stock-surges-on-exceptional-q2-earnings-raised-guidance" target="_blank" rel="noreferrer noopener">SoFi Technologies Stock Surges On &#8216;Exceptional&#8217; Q2 Earnings, Raised Guidance</a></li>
</ul>
Image Via Shutterstock

What's Going On With Eli Lilly Stock On Tuesday?

U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling around 0.2% on Tuesday.
The Dow traded down 0.40% to 44,658.06 while the NASDAQ fell 0.22% to 21,131.59. The S&amp;P 500 also fell, dropping, 0.20% to 6,376.82.
Check This Out: <a href="https://www.benzinga.com/trading-ideas/short-ideas/25/07/46628925/top-2-materials-stocks-that-may-fall-off-a-cliff-this-month">Top 2 Materials Stocks That May Fall Off A Cliff This Month</a>
Leading and Lagging Sectors Real estate shares jumped by 1.5% on Tuesday.
In trading on Tuesday, industrials stocks dipped by 1.2%.
Top Headline
UnitedHealth Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) reported downbeat second-quarter 2025 earnings on Tuesday and reestablished its 2025 guidance.
The insurance giant reported adjusted earnings of $4.08, down from $6.80 a year ago, missing the consensus of $4.95. Revenues increased 13% year over year to $111.62 billion, missing the consensus of $111.69 billion.
UnitedHealth reestablished its fiscal year 2025 guidance, with adjusted earnings of at least $16 per share versus a consensus of $22.33 and sales guidance of $445.5 billion-$448 billion compared to the analyst estimate of $449.5 billion.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul class="wp-block-list">
<li>DURECT Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRRX#NASDAQ">DRRX</a>) shares shot up 271% to $2.0498 after Bausch Health announced plans to acquire the company.</li>
<li>Shares of Sarepta Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) got a boost, surging 25% to $17.27 after the U.S. Food and Drug Administration (FDA) recommended the removal of a voluntary hold for Elevidys.</li>
<li>ScanTech AI Systems Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STAI#NASDAQ">STAI</a>) shares were also up, gaining 102% to $1.35 after the company announced it will offer its technology through the TIPS contract it entered with Creeksource Consulting.</li>
</ul>
Equities Trading DOWN
<ul class="wp-block-list">
<li>AIM ImmunoTech Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIM#NYSE">AIM</a>) shares dropped 54% to $3.3169 after the company announced a $8 million public offering consisting of shares as well as class E and F warrants.</li>
<li>Shares of Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) were down 21% to $54.34 after the company lowered its 2025 sales outlook, citing reduced growth expectations for Wegovy and Ozempic in the US and weaker Wegovy penetration.</li>
<li>WANG &amp; LEE GROUP, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WLGS#NASDAQ">WLGS</a>) was down, falling 42% to $0.0487 after the company announced a 250-to-1 share consolidation.</li>
</ul>
Commodities In commodity news, oil traded up 1.3% to $67.55 while gold traded up 0.5% at $3,326.10.
Silver traded up 0.2% to $38.28 on Tuesday, while copper rose 0.4% to $5.6395.
Euro zone
European shares were higher today. The eurozone's STOXX 600 gained 0.46%, while Spain's IBEX 35 Index gained 0.91%. London's FTSE 100 rose 0.80%, Germany's DAX 40 gained 1.15% and France's CAC 40 rose 0.87% during the session.
Asia Pacific Markets
Asian markets closed mixed on Tuesday, with Japan's Nikkei 225 falling 0.79%, Hong Kong's Hang Seng falling 0.15%, China's Shanghai Composite rising 0.33% and India's BSE Sensex gaining 0.55%.
Economics
<ul class="wp-block-list">
<li>The number of job openings declined by 275,000 to 7.437 million in June, compared to market expectations of 7.55 million.</li>
<li>The S&amp;P CoreLogic Case-Shiller Home Price Index increased 2.8% year-over-year for May.</li>
<li>U.S. wholesale inventories increased 0.2% month-over-month to $907.7 billion in June.</li>
<li>The U.S. trade deficit in goods shrank by $10.4 billion to $86 billion in June.</li>
<li>The Dallas Fed&#8217;s general business activity index rose 6.4 points to a reading of 2 in July.</li>
</ul>
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/07/46658582/top-2-real-estate-stocks-that-may-collapse-this-quarter">Top 2 Real Estate Stocks That May Collapse This quarter</a></li>
</ul>
Photo via Shutterstock

Eurozone

Intraday Update

DRRX

STAI

WLGS

Crude Oil Gains Over 1%; UnitedHealth Earnings Miss Views

Macro Economic Events

Market Summary

Benzinga Market Summary: Novo Nordisk Cuts Guidance, Sofi Rises On Strong Earnings And Outlook, S&P Roughly Flat

Management

Reuters Cites Novo Nordisk Incoming CEO Doustdar Saying We Need To Work On Bringing The Performance Culture Back In The U.S. And Across The Whole Company

Reuters Cites Novo Nordisk Incoming CEO Doustdar Saying There Is A Need To Start Looking For Cost Efficiencies To Fuel Growth; We Must Exercise Greater Discipline And Prudence

Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) suffered its worst trading session on record Tuesday, plunging as much as 25% in European markets after issuing a surprise profit warning tied to its blockbuster obesity drug Wegovy and <a href="https://www.benzinga.com/topic/weight-loss">appointing a new CEO</a>.
<ul class="wp-block-list">
<li>NVO stock is moving fast. <a href="https://www.benzinga.com/quote/NVO">Check the latest price here. </a></li>
</ul>
The Danish pharmaceutical giant now expects 2025 sales to grow 8%–14%, down from a previous range of 13%–21%, and has cut its operating profit forecast to 10%–16%, from 16%–24%. That marks the second guidance cut of the year.
Shares have now fallen 35% year-to-date and are down a staggering 65% from their June 2023 all-time high, wiping out billions in market cap.
Goldman Sachs analyst James Quigley wrote that the reduced expectations were driven by "no change in the compounded semaglutide headwinds and slower-than-expected commercial progress for both Ozempic and Wegovy, with reimbursement access not progressing as planned."
<h3 class="wp-block-heading">Novo Nordisk Crashes 26% in Worst Day On Record</h3>
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="560" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/29090951/image-75-1-1024x560.png" alt="" class="wp-image-1005185" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/29090951/image-75-1-1024x560.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/29090951/image-75-1-300x164.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/29090951/image-75-1-768x420.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/29090951/image-75-1-1536x840.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/29090951/image-75-1-2048x1120.png 2048w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
<h3 class="wp-block-heading">Key Drivers: Compounding, Competition And Slow Reimbursement</h3>
The company blamed ongoing use of compounded semaglutide drugs in the U.S. for undercutting demand for Wegovy, with the CFO&#8217;s estimates suggesting over 1 million patients are on off-brand versions.
Novo has sued telehealth firms like Hims &amp; Hers Health Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>) for marketing what it calls knockoff Wegovy, warning about the risks of illicit or unregulated active ingredients.
Meanwhile, lower-than-expected growth for Ozempic in the U.S. diabetes market and sluggish Wegovy penetration overseas also contributed to the downgrade.
"We expect investors to remain cautious on the outlook for Novo and the obesity market, particularly given the slow resolution of compounding, which has been pushed into at least 2026, and due to concerns about potential further price cuts in order to drive access," Quigley said
<h3 class="wp-block-heading">Leadership Shakeup</h3>
Alongside the downgrade, Novo Nordisk appointed Maziar Mike Doustdar as CEO, effective Aug. 7. Currently head of international operations, Doustdar replaces Lars Fruergaard Jorgensen, ousted in May.
Analysts say Doustdar's challenge will be to expand U.S. Wegovy adoption while scaling international markets and managing intensifying competition from Eli Lilly Co.&#8216;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) Zepbound.
<h3 class="wp-block-heading">Is the Weight-Loss Drug Trade Topping Out?</h3>
With Novo's crash, a broader question looms: Is the weight-loss trade entering correction territory? 
The sharp shift in investor sentiment suggests that valuation multiples may no longer be justified if volume growth stalls and compounding remains unresolved into 2026.
NVO Price Action: Novo Nordisk shares were down 20.36% at $54.95 at the time of publication on Tuesday<a href="https://www.benzinga.com/pro/" target="_blank" rel="noreferrer noopener">, according to Benzinga Pro data.</a>
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/large-cap/25/07/46641084/wall-street-stock-bubble-2025">Is A Stock Market Crash Imminent? Bubble Warnings Grow Louder </a></li>
</ul>
Photo: JHVEPhoto / Shutterstock.com

Analyst Color

Econ #s

Novo Nordisk Implodes After Wegovy Warning—Is The Weight-Loss Bubble Bursting?

<ul>
<li>UNH</li>
<li>NVDA</li>
<li>SOFI</li>
<li>NVO</li>
<li>AMD</li>
<li>GOOGL</li>
<li>GLD</li>
<li>TSLA</li>
<li>SPOT</li>
<li>PYPL</li>
</ul>
Data from <a href="https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment">https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment</a>
&nbsp;

GOOGL

Top 10 Trending Stocks On WallStreetBets As Of July 29, 2025 (Via Swaggy Stocks)

Novo Nordisk Says 'As unsafe and unlawful mass compounding continues, the Wegovy penetration within the cash channel has been lower-than-expected. '

Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>), the Danish pharmaceutical giant renowned for its <a href="https://www.benzinga.com/topic/weight-loss">weight-loss</a> drug Wegovy and diabetes treatment Ozempic, experienced a significant downturn on Tuesday following the company&#8217;s decision to trim its 2025 financial outlook.
This marks the <a href="https://www.benzinga.com/25/05/45252150/novo-nordisk-expects-fda-decision-for-oral-wegovy-by-end-of-2025-reports-mixed-q1-earnings">second time this year</a> the company has revised its guidance downwards, signaling growing headwinds in key markets. Novo Nordisk now projects 2025 sales growth to be in the range of 8-14% at constant exchange rates, a notable reduction from its earlier forecast of 13-21%. 
Similarly, the outlook for operating profit growth has been lowered to 10-16% from the previously anticipated 16-24%. This revised guidance largely stems from a slower-than-expected penetration of its branded GLP-1 treatments, particularly in the United States, a market increasingly impacted by the persistent use of compounded GLP-1 alternatives.
Also Read: <a href="https://www.benzinga.com/news/legal/25/07/46635233/judge-rules-mylan-did-not-infringe-novo-nordisk-patent-in-wegovy-generic-case" target="_blank" rel="noreferrer noopener">Judge Rules Mylan Did Not Infringe Novo Nordisk Patent In Wegovy Generic Case</a>
The company specifically cited lower growth expectations for Wegovy in the U.S. obesity market and for Ozempic in the U.S. GLP-1 diabetes market. Furthermore, Wegovy&#8217;s penetration in certain international markets has also fallen short of expectations, attributing to slower market expansion and heightened competition.
In May, Novo Nordisk already lowered its 2025 guidance, reflecting lower-than-planned penetration of branded GLP-1 treatments in the U.S., impacted by <a href="https://www.benzinga.com/25/05/45252150/novo-nordisk-expects-fda-decision-for-oral-wegovy-by-end-of-2025-reports-mixed-q1-earnings" target="_blank" rel="noreferrer noopener">compounded GLP-1s</a>.
Despite the expiry of the FDA&#8217;s <a href="https://www.globenewswire.com/news-release/2025/07/29/3123109/0/en/Novo-Nordisk-lowers-sales-and-operating-profit-outlook-for-2025.html">grace period</a> for mass compounding on May 22, 2025, Novo Nordisk asserts that unsafe and unlawful mass compounding has continued unabated. The company&#8217;s market research indicates that numerous entities persist in marketing and selling compounded GLP-1s under the guise of &#8220;personalization,&#8221; directly impacting Wegovy&#8217;s penetration within the cash payment channel. 
In response, Novo Nordisk has launched NovoCare Pharmacy in March 2025, which has facilitated approximately 11,000 total weekly Wegovy prescriptions, alongside an additional 20,000 weekly prescriptions in the broader retail cash channel.
In the insured channel, new commercial initiatives for Wegovy launched in the first half of 2025 have not fully offset the slower market expansion and competitive pressures, leading to lower-than-anticipated penetration.
To counter these challenges, Novo Nordisk is actively pursuing multiple strategies, including litigation, to safeguard patients from what it terms &#8220;knockoff &#8216;semaglutide&#8217; drugs.&#8221; This comes amid a broader industry concern, highlighted by a recent letter from over 80 bipartisan U.S. congressional members to FDA Commissioner Marty Makary, urging the agency to curb the proliferation of <a href="https://www.benzinga.com/news/fda/25/07/46641326/congress-sounds-alarm-over-illegal-weight-loss-drug-imports-from-china">counterfeit and copycat</a> GLP-1 drugs.
On a more positive note, Novo Nordisk anticipates a beneficial impact from changes to CVS&#8217;s <a href="https://www.benzinga.com/general/health-care/25/05/45140567/cvs-health-partners-with-wegovy-maker-novo-nordisk-hikes-2025-guidance">national template formulary</a>, effective July 1, 2025, where Wegovy is now the sole GLP-1 medication covered for obesity. The company also continues to invest in commercial activities and label updates to enhance Ozempic&#8217;s market penetration, despite increased competition in the U.S.
Internationally, while Wegovy sales are experiencing robust growth rates and launches are progressing, the revised outlook reflects lower-than-expected penetration in select markets due to slower expansion and competition.
For the first six months of 2025, Novo Nordisk reported an 18% increase in sales and a 29% rise in operating profit at constant exchange rates. These figures were positively influenced by gross-to-net sales adjustments related to prior years, including a significant adjustment of approximately $450 million (3 billion Danish kroner) in the second quarter of 2025 pertaining to the 340B provision. Operating profit growth also benefited from the reversal of an ocedurenone impairment in the second quarter of 2024, partially offset by impacts from the acquisition of three Catalent manufacturing sites.
The company&#8217;s free cash flow is now expected to be in the range of 35-45 billion Danish kroner, a revision reflecting the lower projected sales growth, primarily driven by reduced volume growth of GLP-1-based treatments in the U.S. and associated cash flow implications, further amplified by the intricacies of the U.S. gross-to-net system.
In a key regulatory development, Novo Nordisk expects a regulatory decision regarding the Wegovy Metabolic Dysfunction-Associated Steatohepatitis (MASH) indication during the second half of 2025, which could potentially open up a significant new market for the drug.
<h2 class="wp-block-heading">Leadership Transition</h2>
Adding to the day&#8217;s significant announcements, Novo Nordisk also revealed a leadership change. Maziar Mike Doustdar has been appointed as the new president and chief executive officer, effective August 7, 2025. 
Doustdar, currently Novo Nordisk&#8217;s Executive Vice President of International Operations, will succeed Lars Fruergaard Jørgensen, who will be stepping down from his role.
Price Action: In premarket trading on Tuesday, Novo Nordisk&#8217;s stock plummeted 18.5% to $56.21, reflecting investor apprehension regarding the revised financial projections and the ongoing challenges posed by the compounded drug market.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/07/46683019/byd-surpasses-tesla-in-fortune-global-500-list-amid-sales-slump-for-elon-musks-ev-giant" target="_blank" rel="noreferrer noopener">BYD Surpasses Tesla In Fortune Global 500 List Amid Sales Slump For Elon Musk&#8217;s EV Giant</a></li>
</ul>
Image by KK Stock via Shutterstock

Ozempic And Wegovy Maker Cuts Outlook In Surprise Move, Picks New CEO

U.S. stock futures were higher this morning, with the Nasdaq futures gaining around 100 points on Tuesday.
Shares of Whirlpool Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WHR#NYSE">WHR</a>) fell sharply in pre-market trading after the company reported worse-than-expected second-quarter financial results and cut its <a href="https://www.benzinga.com/quote/WHR">FY25 earnings guidance</a>.
Whirlpool shares dipped 16.3% to $81.93 in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
<ul class="wp-block-list">
<li>Fulcrum Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FULC#NASDAQ">FULC</a>) shares dipped 20% to $6.25 in pre-market trading following second-quarter results.</li>
<li>NeoGenomics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEO#NASDAQ">NEO</a>) declined 14.8% to $5.50 in pre-market trading as the company posted downbeat second-quarter sales and lowered its FY2025 sales guidance.</li>
<li>Harmonic Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HLIT#NASDAQ">HLIT</a>) fell 13.8% to $7.88 in pre-market trading after the company issued third-quarter guidance below estimates.</li>
<li>Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) declined 13% to $60.05 in pre-market trading after the company lowered its 2025 sales outlook, citing reduced growth expectations for Wegovy and Ozempic in the US and weaker Wegovy penetration.</li>
<li>Tilray Brands, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#NASDAQ">TLRY</a>) fell 12.1% to $0.6150 in pre-market trading following weak quarterly sales.</li>
<li>Exelixis, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NASDAQ">EXEL</a>) declined 11% to $39.50 in pre-market trading after the company reported worse-than-expected quarterly revenue results.</li>
<li>Stanley Black &amp; Decker, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SWK#NYSE">SWK</a>) fell 6.6% to $69.00 in pre-market trading following downbeat quarterly sales.</li>
<li>VeriSign, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRSN#NASDAQ">VRSN</a>) fell 6.5% to $286.00 in pre-market trading following a 4.3 million share secondary offering by Berkshire Hathaway to reduce its stake below 10%.</li>
<li>Royal Caribbean Cruises Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RCL#NYSE">RCL</a>) fell 5.5% to $332.49 in pre-market trading after the company issued third-quarter guidance below estimates, despite raising FY25 guidance.</li>
</ul>
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/dividends/25/07/46656981/wall-streets-most-accurate-analysts-give-their-take-on-3-utilities-delivering-high-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Utilities Delivering High-Dividend Yields</a></li>
</ul>
Photo via Shutterstock

Pre-Market Outlook

FULC

HLIT

TLRY

VRSN

Whirlpool Posts Downbeat Earnings, Joins Harmonic, Stanley Black & Decker And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Durect (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRRX#NASDAQ">DRRX</a>) shares moved upwards by 270.9% to $2.05 during Tuesday's pre-market session. The company's market cap stands at $17.1 million. </li>
<li>Salarius Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLRX#NASDAQ">SLRX</a>) shares moved upwards by 150.97% to $1.86. The company's market cap stands at $1.5 million. </li>
<li>Calidi Biotherapeutics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CLDI#AMEX">CLDI</a>) stock rose 50.14% to $0.83. The market value of their outstanding shares is at $18.9 million. </li>
<li>Scinai Immunotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCNI#NASDAQ">SCNI</a>) stock increased by 42.43% to $2.92. The company's market cap stands at $1.9 million. </li>
<li>Sarepta Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) shares rose 37.92% to $19.12. The market value of their outstanding shares is at $1.3 billion. </li>
<li>GeneDx Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WGS#NASDAQ">WGS</a>) stock rose 27.54% to $108.3. The market value of their outstanding shares is at $2.4 billion. As per the news, the Q2 earnings report came out today. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>AIM ImmunoTech (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/AIM#AMEX">AIM</a>) stock decreased by 39.6% to $4.35 during Tuesday's pre-market session. The company's market cap stands at $5.5 million. </li>
<li>Ekso Bionics Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EKSO#NASDAQ">EKSO</a>) stock fell 24.51% to $3.42. The company's market cap stands at $10.7 million. As per the news, the Q2 earnings report came out yesterday. </li>
<li>Novo Nordisk (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) stock fell 20.96% to $54.54. The market value of their outstanding shares is at $306.5 billion. </li>
<li>Fulcrum Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FULC#NASDAQ">FULC</a>) stock decreased by 15.5% to $6.6. The market value of their outstanding shares is at $421.5 million. As per the news, the Q2 earnings report came out today. </li>
<li>NeoGenomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEO#NASDAQ">NEO</a>) stock fell 15.1% to $5.49. The market value of their outstanding shares is at $831.3 million. As per the press release, Q2 earnings came out today. </li>
<li>Catheter Precision (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/VTAK#AMEX">VTAK</a>) stock decreased by 14.15% to $0.19. The company's market cap stands at $2.7 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CLDI

EKSO

SCNI

SLRX

VTAK

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

Press Releases

Novo Nordisk terminates collaboration with Hims & Hers Health, Inc. due to concerns about their illegal mass compounding and deceptive marketing

Securities Fraud Investigation Into Novo Nordisk A/S (NVO) Announced – Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz

Novo Nordisk A/S (NVO) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation

NVO Investors Have Opportunity to Join Novo Nordisk A/S Fraud Investigation with the Schall Law Firm

Securities Fraud Investigation Into Novo Nordisk A/S (NVO) Announced – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm

Novo Nordisk continues efforts to support patient access to authentic, FDA approved Wegovy® and prioritize patient safety

Rosen Law Firm Encourages Novo Nordisk A/S Investors to Inquire About Securities Class Action Investigation – NVO

Securities Fraud Investigation Into Novo Nordisk A/S (NVO) Continues – Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz

Axsome Therapeutics

AstraZeneca PLC - American Depositary Shares

AstraZeneca

Bristol-Myers Squibb Company Common Stock

Bristol-Myers Squibb

Corcept Therapeutics Incorporated - Common Stock

Corcept Therapeutics

Elanco Animal Health Incorporated Common Stock

Elanco Animal Health

GSK plc American Depositary Shares (Each representing two Ordinary Shares)

HUTCHMED (China) Limited - American Depositary Shares

HUTCHMED (China)

Haleon plc American Depositary Shares (Each representing two Ordinary Shares)

Haleon

Jazz Pharmaceuticals plc - Ordinary Shares

Jazz Pharmaceuticals

Johnson & Johnson

Eli Lilly

Merck & Co

Novartis

Organon

Prestige Consumer Healthcare Inc. Common Stock

Prestige Consumer

Pfizer

Dr. Reddy's Laboratories Ltd Common Stock

Dr Reddy's Laboratories

Regencell Bioscience Holdings Limited - Ordinary Shares

Regencell Bioscience

Royalty Pharma plc - Class A Ordinary Shares

Royalty Pharma

Sanofi

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

Takeda Pharmaceutical Co

Teva Pharmaceutical Industries Limited American Depositary Shares

Teva Pharmaceutical Indus

Verona Pharma plc - American Depositary Shares

Verona Pharma

Viatris

Zoetis

BMO Capital

Cantor Fitzgerald

Argus Research

Morgan Stanley

Screenshot 2024-11-20 at 6.30.30 PM

BRTX

BioRestorative Ends Q3 In &#39;Strong&#39; Financial Position, Reports Positive Data For Its Phase 2 BRTX-100 Chronic Back Pain Trial

Screenshot 2024-09-10 at 4.29.40 PM

Armed With Its Patent Portfolio, BioRestorative Therapies Has Success In The Laboratory And At The Negotiating Table: Is Profitability Close Behind?

Screenshot 2024-08-22 at 5.32.58 PM

RDHL

RedHill&#39;s Opaganib Shows Diabetes And Obesity Potential With Positive In Vivo Results

Screenshot 2024-06-18 at 1.15.14 AM

BioRestorative Therapies Enters Preclinical Assessment Of Its Patented Stem-Cell Technology Prior To First-In-Human Studies

Screenshot 2024-05-16 at 5.52.00 PM

ELAB

Elevai Labs (NASDAQ: ELAB) Acquires Rights To Develop Muscle Loss Prevention Assets For Anticipated Use In Anti-Obesity Treatments, Launches Two New Subsidiaries

Screenshot 2024-02-22 at 11.51.01 PM

BTTX

Better Therapeutics Follows Up Wins Including FDA Authorization For AspyreRx In 2023 With Securing FDA Breakthrough Device Designation Targeting Advanced Liver Disease

Comments

Novo Nordisk

Notizie

Ultime notizie per Novo Nordisk (NYSE:NVO) Azioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO